Share Email Print

Proceedings Paper • new

Multiplexed surface-enhanced Raman immunoimaging in vivo with gold nanostars (Conference Presentation)
Author(s): Yu-Chuan Ou; Joseph A. Webb; Christine M. O'Brien; Isaac J. Pence; Eugene C. Lin; Eden P. Paul; Ethan S. Lippmann; Anita Mahadevan-Jansen; Rizia Bardhan
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

The interactions of programmed death protein-1 (PD-1) on T cells with its ligand, PD-L1, strongly contributes to an immunosuppressive microenvironment. Blockades of PD-L1 have shown long-term survival in patients. However, <30% of patients respond to PD-L1 blockade, in part due to inaccurate identification of PD-L1 expression. An unmet clinical need exists for noninvasive detection techniques. Surface-enhanced Raman spectroscopy (SERS) imaging mediated by gold nanostructures has gained interest as a pre-clinical noninvasive diagnostic tool due to the high spatial resolution, portability, low cost, and rapid analysis. In this work, we demonstrate the use of gold nanostars conjugated with Raman tags for multiplexed SERS and simultaneous diagnosis of PD-L1 and epidermal growth factor receptor (EGFR) in vivo. Nanostars conjugated with anti-PDL1 antibodies/DTNB Raman molecule, and nanostars conjugated with anti-EGFR antibodies/pMBA Raman molecules were concurrently introduced to mice. Longitudinal Raman analysis demonstrated maximum accumulation of nanostars occurred 6h post IV delivery when strong increases in SERS signals for both Raman tags were observed. Raman signals decreased by 30% when both targeted receptors were pre-blocked with antibody (IP), indicating both the sensitivity and specificity of our platform in distinguishing tumors with varied expression of PD-L1 and EGFR. Furthermore, ex-vivo Raman maps provided assessment of biomarker status with cellular-resolution, and nanostars distribution in tumors. Finally, gold contents in organs were quantified with inductively coupled plasma mass spectrometry to evaluate their pharmacokinetics and biodistribution. This work shows gold nanostars-mediated SERS imaging provides a quantitative measure of PD-L1 to allow predictive and personalized immunotherapies with minimal toxicities.

Paper Details

Date Published: 4 March 2019
Proc. SPIE 10894, Plasmonics in Biology and Medicine XVI, 108940G (4 March 2019); doi: 10.1117/12.2506699
Show Author Affiliations
Yu-Chuan Ou, Vanderbilt Univ. (United States)
Joseph A. Webb, Vanderbilt Univ. (United States)
Christine M. O'Brien, Vanderbilt Univ. (United States)
Isaac J. Pence, Vanderbilt Univ. (United States)
Eugene C. Lin, Vanderbilt Univ. (United States)
Eden P. Paul, Vanderbilt Univ. (United States)
Ethan S. Lippmann, Vanderbilt Univ. (United States)
Anita Mahadevan-Jansen, Vanderbilt Univ. (United States)
Rizia Bardhan, Vanderbilt Univ. (United States)

Published in SPIE Proceedings Vol. 10894:
Plasmonics in Biology and Medicine XVI
Tuan Vo-Dinh; Ho-Pui A. Ho; Krishanu Ray, Editor(s)

© SPIE. Terms of Use
Back to Top